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Colorectal	cancer	is	the	fourth	most	common	ma-
lignancy	in	the	world,	accounting	for	about	10%	of	all	
cancer	deaths	every	year.	If	patients	were	diagnosed	in	
the	early	stage,	the	overall	five-year	survival	rate	can	be	
around	90%.	However,	about	in	35%	of	cases	tumors	
are	not	detected	until	they	have	invaded	the	surrounding	
tissue	or	metastasized	to	distant	sites.	The	relative	sur-
vival	rate	of	such	patients	is	less	than	40%	[1,	2].	Thus,	
discovery	of	specific	tumor	markers	for	early	diagnosis	
is	of	importance	for	survival	rate	and	prognosis.
Non-invasive	methods	 for	colorectal	cancer	dia-
gnosis	mainly	include	fecal	occult	blood	testing,	fecal	
biochemistry	and	 immunology	 testing,	detection	of	
serum	tumor	markers	and	so	on	[3–5].	All	 these	ap-
proaches	are	neither	sensitive	nor	specific	enough	
for	use	as	the	sole	screening	method	for	early	cancer	
detection.	Novel	gene	technology,	such	as	microarray	
and	DNA	chip,	can	identify	and	quantitative	mRNA	with	
high	sensitivity	on	a	global	scale	[6,	7].	However,	it	has	
been	shown	that	there	is	no	direct	correlation	between	
mRNA	and	protein	expression	level	in vivo	because	of	
post-transcriptional	regulations	and	post-translational	
modifications	occured	in	protein	expression	and	syn-
thesis.	The	mRNA/protein	correlation	coefficients	are	
only	0.4–0.5	and	mRNA	cannot	accurately	represent	the	
quantity	of	protein	which	is	the	true	executant	of	gene	
function	[8–10].	Therefore,	more	extensive	and	effective	
tests	are	desirable	for	diagnosis	of	primary	cancer.
National	Cancer	Institute	(NCI)	gets	a	conclusion	
by	clinical	experiments:	SELDI-TOF-MS	 is	 the	most	
promising	 technology	 for	 early	 detection	 of	 can-
cer	[11].	SELDI-TOF	mass	spectrometry	technology	is	
potentially	an	important	tool	for	the	rapid	identification	
of	 cancer	 specific	biomarkers	and	proteomic	pat-
terns	in	the	proteomes	of	both	tissue	and	body	fluids,	
especially	suitable	for	serum	analysis	which	contains	
abundant	 low	molecular	weight	and	low-abundance	
proteins	that	carry	 important	diagnostic	 information	
but	exist	below	the	detection	limits	of	any	conventional	
testing.	An	advantage	of	this	technology	is	its	ability	
to	simultaneously	analyze	the	whole	proteome	so	that	
correlated	proteins	altered	in	expression	can	be	identi-
fied	in	a	single	experiment.	This	makes	it	possible	to	
combine	several	protein	markers	together	to	form	a	
pattern	with	higher	sensitivity	and	specificity	 in	 the	
detection	and	monitoring	of	cancer.	
The	 aim	 of	 this	 study	was	 to	 compare	 serum	
proteomic	profiles	between	patients	with	colorectal	
cancer,	benign	colorectal	disease	and	healthy	cont-
rols	to	discover	colorectal	cancer-specific	biomarker	
proteins,	and	 to	 validate	 these	biomarkers	with	an	
independent	sample	set.	In	addition,	protein	profiles	
of	patients	with	colorectal	 cancer	before	and	after	
operation	were	also	analyzed.
Materials and Methods
Patients and controls. Two	independent	serum	
sample	sets	were	analyzed	for	their	protein	profiles.	
The	training	set	consisted	of	samples	from	63	patients	
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with	colorectal	cancer	(Dukes’A,	n	=	14,	Dukes’B,	n	=	
19,	Dukes’C,	n	=	17,	Dukes’D,	n	=	13),	20	patients	with	
benign	colorectal	diseases	and	26	healthy	volunteers.	
The	test	set	consisted	of	samples	from	48	patients	with	
colorectal	cancer	(Dukes’A,	n	=	10,	Dukes’B,	n	=	15,	
Dukes’C,	n	=	14,	Dukes’D,	n	=	9),	18	patients	with	
benign	colorectal	diseases	and	14	healthy	volunteers.	
The	mean	age	of	cancer	patients	was	56.7	±	7.3	years	
(range	49–75	years)	while	 the	mean	age	of	control	
group	was	54.2	±	3.5	 years	 (range	46–69	 years).	
There	was	no	statistically	significant	difference	in	the	
ages	between	the	two	groups	(P >	0.05).	Additional	
31	postoperative	patients	with	colorectal	cancer	were	
also	analyzed.	All	the	serum	samples	were	examined	
in	 the	 laboratory	 to	eliminate	diseases	 influenced	
content	of	proteins,	such	as	liver	disease.	The	study	
was	performed	after	approval	by	our	institute	Human	
Investigations	Committee	and	consent	of	all	the	pa-
tients	and	healthy	volunteers.
Samples. 5	ml	of	peripheral	blood	were	collected	
from	the	cancer	patients	and	healthy	subjects.	All	the	
samples	were	collected	before	operation	and	any	
treatment.	For	 the	31	postoperative	patients,	blood	
samples	were	collected	at	the	14th	day	after	opera-
tion.	Each	sample	was	placed	at	4	°C	for	2	h	and	was	
centrifuged	at	3000	r/min	for	10	min	to	remove	cel-
lular	components.	Serum	samples	were	collected,	
aliquoted	and	kept	 frozen	at	–80	°C	until	use.	CEA,	
CA199,	CA242	levels	were	examined	previously.
SELDI analysis. Four	 types	of	chip	 (hydropho-
bic	chip,	strong	anion	exchanger	chip,	weak	cation	
exchanger	chip	and	 immobilized	metal	anion	chip)	
were	 tested	 to	determine	which	could	provide	 the	
best	serum	profiles.	After	evaluation,	the	weak	cation	
exchanger	(WCX)	Protein	Chip	which	contains	anionic	
carboxylate	groups	that	bind	positively	charged	pro-
teins	in	serum	was	selected	for	our	study.
Serum	samples	were	denatured	by	adding	20	μl	U9	
(9	M	urea,	2%	CHAPS,	50	mM	Tris-HCl,	pH	=	9.0)	
to	10	μl	 serum,	 then	adding	360	μl	binding	buffer.	
Subsequently,	150	μl	denatured	samples	was	applied	
on	Protein	Chip	which	had	previously	been	activated	
with	10	mM	HCl	and	equilibrated	with	binding	buffer	
(100	mM	ammonium	acetate)	according	to	the	manu-
facturer’s	instructions.	After	the	samples	were	allowed	
to	incubate	for	60	min	on	a	platform	shaker,	the	array	
was	washed	twice	with	200	μl	binding	buffer	for	5	min,	
followed	by	two	quick	rinses	with	HEPES	solution.	Be-
fore	SELDI	analysis,	0.5	μl	of	a	saturated	SPA	solution	
(sinapinic	acid	in	50%	aqueous	acetonitrile	and	0.5%	
trifluoroacetic	acid)	was	applied	onto	each	chip	array	
twice,	allowing	the	array	surface	to	air-dry	between	
each	SPA	application.	Chips	were	placed	on	the	Protein	
Biological	System	 II	mass	spectrometer	 reader	and	
time-of-flight	spectra	were	generated	by	averaging	
60	laser	shots	collected	in	the	positive	mode	at	laser	
intensity	165	and	detector	sensitivity	8.	Mass	accuracy	
was	calibrated	on	the	day	of	measurements	using	the	
All-in-one	peptide	molecular	mass	standard.
The	reproducibility	of	SELDI	spectra,	that	is,	mass	
location	and	intensity	from	array	to	array	on	a	single	
chip	 (intra-assay)	and	between	chips	 (interassay),	
was	determined	using	the	pooled	normal	serum	quali-
ty	control	 (QC)	sample.	We	compared	 the	average	
intensity	of	all	peaks	in	the	range	of	2000–30000	Da	
observed	on	spectra	and	calculated	the	coefficient	of	
variance.	The	 intra-assay	analyses	were	performed	
in	quadruplicate,	and	the	 inter-assay	analyses	were	
performed	on	three	different	days.
Statistical analysis. Peak	detection	was	per-
formed	using	Ciphergen	ProteinChip	software	 ver-
sions	3.2.	The	mass	 range	 from	2000	 to	30000	Da	
was	selected.	We	focused	on	this	region	to	eliminate	
low-mass	 (m/z	<	 2000)	 and	 low-intensity	 peaks	
(m/z	>	30000).	Peak	detection	involved	(a)	baseline	
subtraction,	 (b)	mass	accuracy	calibration	and	 (c)	
automatic	peak	detection.	Using	Biomarker	Wizard	
(BMW)	software,	biomarkers	were	generated	which	
represented	 consistent	 protein	 peak	 sets	 across	
multiple	spectra.	Next,	Biomarker	Patterns	software	
(BPS)	was	used	to	construct	the	decision	tree	from	the	
BMW	files.	The	value	of	the	candidate	biomarkers	in	
detecting	colorectal	cancer	from	non-cancer	controls	
was	evaluated	by	Mann	—	Whitney U test.	Mean	spect-
ra	generated	 from	preoperative	and	postoperative	
groups, patients	with	primary	colorectal	cancer	and	
metastatic	colorectal	cancer	were	compared	using	
Students t-test.
Serum CEA, CA199 and CA242 quantification.	
Serum	CEA,	CA199	and	CA242	were	quantified	us-
ing	an	electrochemiluminiscence	immunoassay	on	a	
Modular	analytics	E170	analyser.	The	cut-off	value	of	
5	ng/mL,	35	KU/L	and	20	KU/L	were	employed	for	CEA,	
CA199	and	CA242	respectively.	All	statistical	analyses	
for	these	data	were	performed	with	SPSS	software.
results
Reproducibility. The	 reproducibility	 of	SELDI	
mass	spectra	was	successfully	testified	using	the	quali-
ty	control	 (QC)	samples.	The	 intra-	and	 inter-assay	
coefficients	of	variance	 for	peak	 location	were	0.04	
and	0.05%,	and	the	intra-	and	inter-assay	coefficients	
of	 variance	 for	normalized	 intensity	 (peak	height	or	
relative	concentration)	were	respectively	11	and	14%.	
There	was	little	variation	with	day-to-day	sampling	and	
instrumentation.	The	acceptable	intra-	and	inter-assay	
variations	of	this	method	have	allowed	us	to	obtain	a	
reliable	result	in	this	study.
Cancer-specific biomarkers detection and se-
lectivity. A	total	of	127	peaks	were	identified	in	the	m/z	
region	of	2000–30	000	from	SELDI	spectra	of	training	
set.	Using	Biomarker	Wizard	software,	we	compared	
the	spectra	generated	from	cancer	group	with	corre-
sponding	spectra	generated	from	control	group.	This	
comparison	yielded	26	differential	peaks	 (Table	1).	
Among	these,	4	peaks	were	chose	to	 form	a	model	
that	could	discriminate	colorectal	cancer	patients	from	
control	group	effectively.	The	4	peaks	corresponded	
to	m/z	 ratios	of	3191.5,	3262.9,	3396.3	and	5334.4	
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(Table	2,	Fig.	1).	All	 the	4	peaks	were	up-regulated	
in	 the	group	of	patients	with	colorectal	cancer	 (P <	
0.01).	The	sensitivity	and	specificity	of	this	model	was	
respectively	90.3	and	95.7%.	A	blind	test	set	consisted	
of	48	patients	with	colorectal	cancer,	18	patients	with	
benign	colorectal	neoplasia	and	14	healthy	volunteers.	
In	our	study,	correctly	classification	was	achieved	in	30	
of	32	controls	and	42	of	48	cancer	patients,	including	
8	of	10	Duke’A	patients.
Table 1. Differently expressed proteins in serum of colorectal cancer 
group and control group
Mass-charge ratio 
of protein (m/z) P value
The average intensity of protein peak
Colorectal cancer group Control group
2753.8 0.00004 31.11608654 12.1590982
9289.3 0.00003 24.35909 13.14588
5334.4* 0.00002 22.73111 6.084794
3191.5* 0.0009 7.725975 2.0018
4645.9 0.0009 11.21654 5.426459
3262.9* 0.001 10.033386 3.291793
4172.4 0.001 19.398129 5.92417203
5803.7 0.001 7.97111 1.900566
14123.7 0.001 2.656011 4.71362
14023.8 0.001 4.604952 7.730591
28024.4 0.001 8.792696 15.22274
2963.9 0.002 7.322281 1.991357
5904.1 0.002 42.15694 14.6972
2949.8 0.002 19.81355 5.610585
5831.7 0.002 6.03706 2.348323
3396.3* 0.002 23.88053 8.67945
28858.68 0.002 1.792869 3.191014
13742.1 0.003 2.209401 3.782254
5263.0 0.005 5.592539 1.753355
4671.9 0.007 4.737961 2.475495
5745.4 0.01 2.134776 1.351598
2899.9 0.01 3.988201 0.886663
7971.9 0.01 15.78563 10.27681
15841.9 0.02 13.43144 7.96911
11795.6 0.02 5.15713 1.362526
23369.7 0.04 6.67954 8.803534
The proteomic spectra indicated the average intensity of differently ex-
pressed proteins in two groups. The four peaks that constructed diagnos-
tic model were marked by * sign.
Table 2. Differently expressed proteins in blood serum of  preoperative 
and postoperative groups
Mass-charge ratio 
of protein (m/z) P value
The average intensity of protein peak
Preoperative group Postoperative group
2753.8 0.00005 31.21516847 11.2172390
4172.4 0.001 20.0139783 5.78351392
CA199,	CA242	and	CEA	levels	were	available	for	
all	the	cases	in	training	set	and	test	set.	We	found	that	
combination	of	these	three	markers	had	the	sensitivity	
of	62.4%	and	specificity	of	86.2%	for	distinguishing	
colorectal	cancer	from	controls.	Obviously,	 the	pro-
teomic	model	generated	 from	our	study	had	higher	
sensitivity	 than	 the	combination	of	CA199,	CA242	
and	CEA	for	diagnosing	colorectal	cancer	(P <	0.005)	
though	the	specificity	had	no	statistic	difference.
Different preoperative and postoperative 
markers in colorectal cancer.	We	compared	 the	
preoperative	protein	profiles	with	 the	postoperative	
(day	14)	profiles	for	the	31	colorectal	cancer	patients.	
Two	peaks	(m/z:	2753.8	and	4172.4,	Fig.	2)	were	de-
tected	which	were	down-regulated	in	27	of	31	(87.5%)	
patients	compared	to	these	in	preoperative	samples.	
In	an	independent	test	set,	the	two	peaks	were	also	
validated	down-regulated	in	13	of	16	(81.3%)	postope-
rative	samples.
fig. 1. (a, b)	 Proteomic	 pattern	 of	 blood	 serum	 samples	
of	 colorectal	 cancer	 patients	 and	 controls	 evaluated	 by	
SELDI-TOF-MS.	X-axis	represents	the	ratio	of	mass	to	charge	
of	 protein,	 Y-axis	 represents	 relative	 intensity.	 The	profiles	
demonstrate	up-regulation	of	m/z	3191.5,	3262.9,	3396.3	and	
5334.4	peaks	in	colorectal	cancer	patients
Differential markers for primary colorectal 
cancer and metastatic colorectal cancer.	 The	
cancer	patients	of	the	training	set	were	divided	into	two	
groups	(30	patients	with	metastasis	and	33	patients	
without	metastasis)	according	to	after	surgical	exami-
nation.	Two	proteins	(m/z:	9184.4	and	9340.9,	Fig.	3)	
were	found	that	can	discriminate	the	two	groups.	The	
two	proteins	were	observed	in	all	the	Duke’A	and	in	13	
of	15	Duke’B	patients,	absent	in	11	of	14	Duke’C	and	
all	Duke’D	patients	from	the	test	set.
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fig. 2. (a, b)	Proteomic	pattern	of	blood	serum	samples	of	
preoperative	patients	and	postoperative	patients	evaluated	by	
SELDI-TOF-MS.	X-axis	represents	the	ratio	of	mass	to	charge	
of	 protein,	 Y-axis	 represents	 relative	 intensity.	 The	profiles	
demonstrate	up-regulation	of	m/z	2753.8	and	4172.4	peaks	in	
preoperative	patients
discussion
Although	diagnostic	 technology	and	 therapeutic	
treatment	have	made	vast	progress	during	 the	 last	
decades,	the	survival	rate	of	patients	with	colorectal	
cancer	still	has	no	significant	 improvement.	Without	
useful	method	for	early	cancer	detection	 is	 thought	
to	be	responsible	for	this.	Currently,	CEA	is	the	best	
available	marker	for	colorectal	cancer	detection.	How-
ever,	the	use	of	CEA	has	significant	clinical	limitation	
because	of	low	sensitivity	(3–66.7%)	[4,	12,	13].	Con-
siderable	effort	has	been	taken	in	identifying	potential	
markers	that	might	substitute	or	complement	CEA	in	
screening	colorectal	cancer.	
fig. 3. Proteomic	pattern	of	blood	serum	samples	of	colorec-
tal	cancer	patients	with	and	without	metastasis	evaluated	by	
SELDI-TOF-MS.	X-axis	represents	the	ratio	of	mass	to	charge	
of	protein,	Y-axis	represents	relative	intensity.The	profile	dem-
onstrates	absence	of	m/z	9184.4	and	9340.9	peaks	in	patients	
with	metstatic	colorectal	cancer
SELDI-TOF-MS	is	a	new	type	of	proteomic	platform	
which	has	recently	shown	tremendous	promise	in	the	
detection	of	various	early-stage	cancers,	such	as	breast,	
ovarian,	prostate,	gastric	cancer	and	so	on	[14–17].	It	
is	especially	suitable	for	examination	of	small	volumes	
of	samples	such	as	serum	which	has	been	proven	to	
be	a	rich	source	of	biomarker	for	the	early	detection	
of	cancer	[18].	Contrary	to	genome	and	other	conven-
tional	approaches,	this	method	can	reflect	not	only	the	
presence	of	active	or	inactive	genes	but	also	their	extent	
of	expression	at	a	specific	time	point.	Furthermore,	it	
can	detect	all	proteins	and	peptides	that	may	originate	
from	the	same	gene	but	with	different	post-translation	
modifications.	Using	SELDI-TOF-MS,	novel	proteins	
specific	to	certain	cancer	and	characterization	of	these	
proteins	can	be	discovered	and	captured	by	compara-
tive	analysis	of	the	mass	spectra	of	the	samples	from	
patients	and	normal	controls.
In	 this	study,	SELDI-TOF-MS	was	applied	 to	es-
tablish	serum	protein	pattern	for	screening	colorectal	
cancer.	We	compared	protein	spectra	 from	patients	
who	had	colorectal	 cancer	with	 the	corresponding	
spectra	from	healthy	controls	and	patients	with	benign	
colorectal	disease.	Our	analysis	yielded	a	proteomic	
model	 consisting	 of	 4	 candidate	makers	 (m/z	 of	
3191.5,	3262.9,	3396.3	and	5334.4)	which	were	all	
up-regulated	in	cancer	patients.	Several	reports	have	
been	made	of	differential	expression	of	the	same	m/z	
values	in	colorectal	cancer,	even	though	different	chips	
were	used.	 In	 the	study	 [1]	 it	was	 reported	a	3.3	×	
103	Da	protein	to	be	differentially	expressed	that	was	
also	selected	 in	 the	 final	diagnostic	pattern.	Yu	 [10,	
19]	detected	a	5.9	×	103	Da	protein	on	a	hydrophobic	
chip	which	was	an	up-regulated	biomarker	in	serum	
of	colorectal	cancer	patients.	Although	we	did	not	se-
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lect	the	5904.6	Da	protein	to	form	the	final	diagnostic	
pattern,	it	was	truly	differentially	expressed	in	cancer	
patients	with	controls	which	is	consistent	with	the	result	
[10,	19].	An	effective	screening	test	should	achieve	a	
high	sensitivity	and	specificity.	We	were	encouraged	to	
find	that	the	proteomic	pattern	resolved	by	SELDI	may	
become	a	potential	diagnostic	approach	with	sensitiv-
ity	of	90.3%	and	specificity	of	95.7%	in	training	set	and	
was	validated	with	high	sensitivity	and	specificity	in	test	
set.	This	study	showed	that	our	proteomic	biomarkers	
was	significantly	better	than	the	combination	of	routine	
markers	CEA,	CA199	and	CA242.	Eight	from	ten	Duke’A	
patients	from	test	set	were	correctly	classified	by	pro-
teomic	model	but	none	by	 the	combination	of	CEA,	
CA199	and	CA242.	Thus,	 these	proteomic	markers	
may	facilitate	early-detection	of	colorectal	cancer.
Finding	biomarkers	to	monitor	treatment	response	
is	an	issue	in	tumor	research.	We	analyzed	proteomic	
changes	 in	 the	serum	of	postoperative	patients	with	
colorectal	 cancer	before	and	after	operation.	Two	
peaks	(m/z:	2753.8	and	4172.4)	were	detected	which	
were	down-regulated	 in	postoperative	samples	 than	
preoperative	samples.	The	two	proteins	were	both	dif-
ferential	biomarkers	between	colorectal	cancer	patients	
and	non-cancer	controls	and	the	mean	peak	intensity	
were	approximately	three	times	in	preoperative	patients	
than	postoperative	patients.	We	hypothesized	that	these	
two	biomarker	may	be	oncogene	proteins	and	provide	
a	new	insight	into	therapeutic	strategies	and	molecular	
mechanism	behind	the	process	of	tumorigenesis.
Colorectal	caner	metastasis	is	a	complex	process	
involving	multiple	changes	 in	gene	and	protein	ex-
pression	[20–22].	The	success	of	metastatic	cancer	
treatment	 is	strongly	dependent	on	early	diagnosis	
and	understanding	of	the	molecule	mechanisms	and	
biological	behaviors,	especially	its	infiltration	and	me-
tastasis.	To	our	knowledge,	there	is	no	reports	about	
serum	proteomics	of	metastatic	colorectal	cancer	by	
SELDI-TOF	MS	before.	In	this	study,	the	identification	of	
differential	proteins	between	primary	colorectal	cancer	
and	metastatic	cancer	was	also	performed.	Two	peaks	
(m/z:	9184.4	and	9340.9)	were	found	that	can	discrimi-
nate	the	two	groups.	The	two	proteins	were	observed	in	
all	the	Duke’A	and	13	of	15	Duke’B	patients	and	absent	
in	11	of	14	Duke’C	and	all	Duke’D	patients	from	the	test	
set.	We	concluded	that	these	two	biomarkers	may	be	
metastasis	related	proteins	and	can	be	used	to	monitor	
micrometastasis	at	the	early	stage.
In	conclusion,	our	study	has	proved	 that	SELDI-
TOF-MS	is	a	very	useful	and	promising	tool	to	detect	
new	serum	tumor	biomarkers.	These	protein	markers	
will	enable	a	more	reliable	early	diagnosis	of	colorectal	
cancer	and	facilitate	the	prediction	of	their	progres-
sion.	To	confirm	our	findings	in	larger	number	of	study	
samples	and	identify	the	reported	biomarker	proteins,	
a	prospective	study	is	recently	ongoing.
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скрининг спектра белков сыворотки крови больных 
колоректальным раком методом seldi-tof-Ms
Цель: исследование белкового профиля сыворотки крови больных колоректальным раком и здоровых доноров методом 
SELDI-TOF-MS для диагностики заболевания и мониторинга микрометастазов.       Методы: методом SELDI-TOF-MS 
исследованы сыворотки крови 63 больных колоректальным раком, 20 больных с доброкачественными новообразованиями 
прямой кишки и 26 — здоровых доноров. Проведено сравнение профилей белков сыворотки крови 31 больного до и после 
хирургического вмешательства, а также больных с метастазами или без таковых. Результаты: получена 4-пиковая модель 
(m/z: 3191,5�� 3262,9�� 3396,3 и 5334,4), позволя��ая отличить опухолевые образ�ы от неопухолевых с чувствительность�              
90,3% и спе�ифичность� 95,7%. �акая модель проверена в тест-системе с чувствительность� 87,5% и спе�ифичность�             
93,8%, что является лучшим результатом, чем комбинированное применение CEA, CA199 и CA242 (чувствительность     
62,4%) для раннего выявления колоректального рака. Выявлено снижение интенсивности двух пиков (m/z: 2753,8 и   
4172,4) при сравнении образ�ов до и после проведения опера�ии, и идентифи�ированы два белка (m/z: 9184,4 и 9340,9),    
позволя��ие выявлять больных колоректальным раком с метастазами. Выводы: полученная модель и результаты работы 
могут быть полезны для диагностики колоректального рака и мониторинга метастазирования. 
Ключевые слова: SELDI-TOF, протеом, колоректальный рак, биомаркер, метастазирование.     
